CTRI Number |
CTRI/2021/06/033918 [Registered on: 01/06/2021] Trial Registered Prospectively |
Last Modified On: |
28/05/2021 |
Post Graduate Thesis |
No |
Type of Trial |
Interventional |
Type of Study
|
Probiotic |
Study Design |
Randomized, Parallel Group Trial |
Public Title of Study
|
Efficacy of Bacillus Clausii in Acute Diarrhoea in Children |
Scientific Title of Study
|
An Open Labelled Study on Clinical Efficacy of Bacillus Clausii in Management of Acute Diarrhoea in Children |
Trial Acronym |
|
Secondary IDs if Any
|
Secondary ID |
Identifier |
NIL |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Ramanath A |
Designation |
Professor and Head of the Department |
Affiliation |
Panimalar Medical College Hospital and Research Institute, |
Address |
Department of Pediatrics
Panimalar Medical College and Hospital Research Institute
Varadharajapuram
Poonamallee,
Chennai TAMIL NADU 600123 India |
Phone |
9884750160 |
Fax |
|
Email |
chandra.ramanath82@gmail.com |
|
Details of Contact Person Scientific Query
|
Name |
Ramanath A |
Designation |
Professor and Head of the Department |
Affiliation |
Panimalar Medical College Hospital and Research Institute, |
Address |
Department of Pediatrics
Panimalar Medical College and Hospital Research Institute
Varadharajapuram
Poonamallee,
Chennai TAMIL NADU 600123 India |
Phone |
9884750160 |
Fax |
|
Email |
chandra.ramanath82@gmail.com |
|
Details of Contact Person Public Query
|
Name |
Ramanath A |
Designation |
Professor and Head of the Department |
Affiliation |
Panimalar Medical College Hospital and Research Institute, |
Address |
Department of Pediatrics
Panimalar Medical College and Hospital Research Institute
Varadharajapuram
Poonamallee,
Chennai TAMIL NADU 600123 India |
Phone |
9884750160 |
Fax |
|
Email |
chandra.ramanath82@gmail.com |
|
Source of Monetary or Material Support
|
Tablets India Limited
72 Marshalls Road
Egmore
Chennai 600008 |
|
Primary Sponsor
|
Name |
Tablets India Limited |
Address |
Jhaver center
72 Marshalls Road
Egmore
Chennai 600008 |
Type of Sponsor |
Pharmaceutical industry-Indian |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Ramanath A |
Panimalar Medical College Hospital and Research Institute |
Department of Pediatrics
Varadharajapuram
Poonamallee
Chennai 600123
Chennai TAMIL NADU |
9884750160
chandra.ramanath82@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
Panimalar Medical College Hospital and Research Institute - Institutional Human Ethics Committee (PMCHRI-IHEC) |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition: K928||Other specified diseases of the digestive system, |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Intervention |
Bacillus Clausii 2 billion CFU |
Bacillus clausii 2 billion probiotic for kids –
Maintains the right kind of gut flora balance
Restores internal bacterial balance to help improve immunity
Provides gentle gut care for your child
Helps in restoring the natural balance of gut bacteria
Addresses the root cause of digestive troubles such as diarrhoea and the like and promotes faster return of bacterial balance in the gut.
Contributes to correct dysvitaminosis- which is the imbalance of production and assimilation of vitamins
Works as effective diarrhoea management
Dose Bacillus Clausii 2 billion CFU, two times a day, Route of administration per oral and duration five days |
Comparator Agent |
Oral Rehydration Syrup (ORS) for children |
The ORS for children works by neutralizing excess acid in the blood and urine
Has been indicated for the treatment of metabolic acidosis
Helps to restore lost electrolytes and fluids in the body
Aids in the treatment dehydration caused by diarrhea, vomiting
Dose Oral Rehydration Syrup two times a day,
Route of administration per oral
Duration of therapy five days |
|
Inclusion Criteria
|
Age From |
6.00 Month(s) |
Age To |
10.00 Year(s) |
Gender |
Both |
Details |
Children aged between 6 months and 10 years with acute bacterial gastroenteritis or acute viral gastroenteritis.
Acute diarrhea for a duration of <3 days.
|
|
ExclusionCriteria |
Details |
Severe dehydration and electrolyte imbalance
Presence of systemic infections
Children with known immunocomprising morbidities
Children with chronic or severe respiratory, cardiovascular, central nervous system, endocrine and other gastrointestinal disorders on clinical examination.
|
|
Method of Generating Random Sequence
|
Stratified block randomization |
Method of Concealment
|
An Open list of random numbers |
Blinding/Masking
|
Open Label |
Primary Outcome
|
Outcome |
TimePoints |
1.No. of stools per day after 24 hours of treatment
2.No. of stools per day after 48 hours of treatment
3.Duration of diarrhoea in days
|
1.No. of stools per day after 24 hours of treatment
2.No. of stools per day after 48 hours of treatment
3.Duration of diarrhoea in days
|
|
Secondary Outcome
|
Outcome |
TimePoints |
1.No. of episodes of vomiting
2.Changes in Stool consistency from 24 hrs to 48 hrs.
3.Body weight at baseline and day 5.
|
24 hrs to 48 hrs and Day 5 |
|
Target Sample Size
|
Total Sample Size="50" Sample Size from India="50"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
Phase 4 |
Date of First Enrollment (India)
|
03/06/2021 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
Recruitment Status of Trial (Global)
|
Not Applicable |
Recruitment Status of Trial (India) |
Not Yet Recruiting |
Publication Details
|
Nil |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - YES
- What data in particular will be shared?
Response - All of the individual participant data collected during the trial, after de-identification.
- What additional supporting information will be shared?
Response - Study Protocol Response - Statistical Analysis Plan Response - Informed Consent Form Response - Analytic Code
- Who will be able to view these files?
Response - Anyone
- For what types of analyses will this data be available?
Response - Any purpose.
- By what mechanism will data be made available?
Response (Others) -
- For how long will this data be available start date provided 21-05-2021 and end date provided 21-10-2025?
Response - Immediately following publication. No end date.
- Any URL or additional information regarding plan/policy for sharing IPD?
Additional Information - None
|
Brief Summary
|
Acute gastroenteritis is an infectious syndrome that represents
the first cause of hospitalization in children1.Diarrhea is usually
a symptom of an infection in the intestinal tract, which can be caused by a
variety of bacterial, viral and parasitic organisms. Infection is spread
through contaminated food or drinking water, or from person-to-person as a
result of poor hygiene2. Diarrhea due to infection is widespread throughout
developing countries. In developing countries, children under 5 years of age
experience on average three episodes of diarrhea every year3.One out
of every five children who die of diarrhea worldwide is an Indian. Repeated
episodes of diarrhea in children can result in long-term deleterious effects on
nutritional status, possibly due to intestinal damage. Each episode deprives
the child from the basic nutrition necessary for growth. As a result, diarrhea
is a major cause ofmalnutrition, and malnourished children are more likely to
fall ill from diarrhea2.The
management of acute diarrhoea consists of the replacement of lost fluid with
glucose-electrolyte oral rehydration solution. This solution, however, reduces
neither the severity nor the duration of diarrhoea4 but has
substantial benefit in preventing major morbidities due to dehydration and even
mortality. The need of the hour is such agents which reduces both severity and
duration of diarrhoea without any major impact on the motility retardation.
Probiotics are live microbial feed supplements that beneficially
affect the host by improving its microbial balance. They are commonly used in
the treatment and prevention of acute diarrhea. The rationale for using
probiotics in acute infectious diarrhea is based on the assumption that they
act against intestinal pathogens5 through a variety of physiological
and mechanical hostility to pathogens.
Out of many probiotics available, Bacillus Clausii is found to be beneficial in reducing prevalence,
duration and severity of diarrhea6. This study is aimed to evaluate
efficacy of Bacillus Clausii in
treatment of acute diarrhea in children. |